期刊文献+

122例朗格汉斯细胞组织细胞增生症临床分析 被引量:18

Clinical Analysis of 122 Cases of Langerhans Cell Histiocytosis
在线阅读 下载PDF
导出
摘要 目的探讨朗格汉斯细胞组织细胞增生症(LCH)的疾病特点。方法回顾性分析北京协和医院收治的122例LCH患者皮损表现、系统受累表现、影像学表现、实验室检查、免疫表型及治疗和预后情况。结果 LCH皮损形态多样,最常受累的器官为肺,其他易受累的部位有骨、皮肤、淋巴结、肝脏、脾脏、口腔、甲状腺等。多系统LCH患者较单系统LCH患者多见。单系统LCH多采用手术治疗,多系统LCH以联合化疗为主。结论 LCH临床表现多样,肺是最常见的受损器官;治疗可采用手术或化疗。 Objective To investigate the features of Langerhans cell histiocytosis( LCH). Method Skin lesions, systemic involvement, imaging characteristics, laboratory tests, immunophenotying, treatment response,and survival of 122 LCH patients treated at our center from February 1983 to August 2013 were retrospectively analyzed. Results LCH was associated with diverse skin lesions. Lung was the most involved organ,followed by bone, skin, lymph nodes, liver, spleen, oral cavity, and thyroid. Multisystem LCH was more common than single-system LCH. Single-system LCH was mostly treated by surgery,whereas multisystem LCH by combined chemotherapy. Conclusions LCH has diverse clinical manifestations,with lungs being the most often involved organ. Surgery or chemotherapy is the mainstream treatment.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2017年第2期206-210,共5页 Acta Academiae Medicinae Sinicae
关键词 朗格汉斯细胞组织细胞增生症 临床分析 回顾性 治疗 Langerhans cell histiocytosis clinical analysis retrospective treatment
作者简介 通信作者:刘跃华,电话:010-69151502,电子邮件:yuehualiu@263.net
  • 相关文献

参考文献2

二级参考文献32

  • 1王宏胜,李军,马伴吟,高怡瑾,陆凤娟,钱晓文.改良DAL-HX83/90方案治疗儿童郎格罕细胞组织细胞增生症24例疗效观察[J].中国小儿血液与肿瘤杂志,2007,12(2):60-63. 被引量:12
  • 2Histiocyte Society. Langerhans cell histiocytosis evaluation and treatment guideline. April,2009. Availabele from : http ://www. heamatologie-amc, nl/odijk/bijlagen.
  • 3Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs, 2011,13 : 75 -86.
  • 4Gadner I-I, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histioeytosis. J Pediatr, 2001, 138:728-734.
  • 5treatment ot multisystem Langerhans cell histiocytosis : important prognostic indicator. Med Pediatr Oncol, 2002,39:581- 585.
  • 6Bernard F, Thomas C, Bertrand Y,et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside corobined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer, 2005,41:2682-2689.
  • 7Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced- intensity conditioning. Bone Marrow Transplant, 2005,36: 215- 225.
  • 8Egeler RM, de Kraker J, Vo6te PA. Cytosine-arabinoside, vincristine, and prednisolone in the treatment of children with disseminated Langerhans cell histiocytosis with organ dysfunction: experience at a single institution. Med Pediatr Oncol, 1993,21: 265-270.
  • 9Stine KC, Saylors RL, Williams LL, et al. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol, 1997,29: 288-292.
  • 10Stine KC, Saylors RL, Saccente S, et al. Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. Pediatr Blood Cancer, 2004,43:81-84.

共引文献88

同被引文献113

引证文献18

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部